← Leaderboards
Jonathan Eric Rosenberg
Sloan-Kettering Inst Can Research
$1,981,747
Attributed
$1,981,747
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2012–24$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,878,022 · 3
By mechanism
P50$2,423,982 · 2
R21$454,040 · 1
Top collaborators
- David B. Solit1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- David B. Solit$21,393,031
- Eirini Papapetrou$13,419,805
- Hikmat Al-Ahmadie$4,559,862
- Timothy An-Thy Chan$21,076,830
- Richard N Kolesnick$17,601,323
Others in their field
Top investigators on “Genomics”
- Eric S Lander · Whitehead Institute For Biomedical Res$790,826,794
- Richard A Gibbs · Baylor College Of Medicine$661,700,875
- Richard K. Wilson · Washington University$497,388,134
- Leonard Freedman · Leidos Biomedical Research, Inc.$405,398,682
- David Heimbrook · Leidos Biomedical Research, Inc.$333,649,126
- Stacey Gabriel · Massachusetts Institute Of Technology$331,896,891
Research focus
GenomicsMalignant NeoplasmsTumorRecurrenceRandomizedResistanceResistance MechanismMalignant Neoplasm Of Urinary BladderMutationMolecularPredictive MarkerProspectiveImmunotherapyResearch Project GrantsFda ApprovedImmune Checkpoint BlockadeBloodImmune Checkpoint InhibitorChemotherapyClinical TrialsImproved OutcomeMinorityCombinatorialPatient Subsets
Grant awards (7)
SPORE in Bladder Cancer$896,275
P50 · FY2024 · CA · contact PI
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers$235,745
P50 · FY2024 · CA · contact PI
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers$343,314
P50 · FY2022 · CA · contact PI
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers$592,269
P50 · FY2021 · CA · contact PI
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers$356,379
P50 · FY2020 · CA · contact PI
Evaluation of a novel urothelial cancer biomarker of lethality$184,770
R21 · FY2013 · CA · contact PI
Evaluation of a novel urothelial cancer biomarker of lethality$269,270
R21 · FY2012 · CA · contact PI